QS Investors LLC maintained its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,569 shares of the company’s stock at the close of the 2nd quarter. QS Investors LLC owned 0.18% of Amphastar Pharmaceuticals worth $1,457,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Amphastar Pharmaceuticals by 10.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,414,797 shares of the company’s stock worth $43,128,000 after purchasing an additional 235,033 shares during the period. Dimensional Fund Advisors LP grew its position in Amphastar Pharmaceuticals by 25.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,331,842 shares of the company’s stock worth $23,786,000 after purchasing an additional 270,654 shares during the period. State Street Corp grew its position in Amphastar Pharmaceuticals by 11.1% in the 1st quarter. State Street Corp now owns 1,062,439 shares of the company’s stock worth $15,406,000 after purchasing an additional 106,448 shares during the period. Teachers Advisors LLC grew its position in Amphastar Pharmaceuticals by 1.1% in the 2nd quarter. Teachers Advisors LLC now owns 549,149 shares of the company’s stock worth $9,808,000 after purchasing an additional 6,196 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Amphastar Pharmaceuticals by 11.4% in the 1st quarter. Bank of New York Mellon Corp now owns 519,802 shares of the company’s stock worth $7,536,000 after purchasing an additional 53,214 shares during the period. 44.26% of the stock is owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) opened at 18.70 on Wednesday. Amphastar Pharmaceuticals, Inc. has a 1-year low of $12.05 and a 1-year high of $21.75. The stock has a market cap of $863.85 million, a PE ratio of 242.86 and a beta of 1.69. The company’s 50 day moving average is $16.58 and its 200-day moving average is $16.23.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.05. The company had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The firm’s revenue was down 4.1% on a year-over-year basis. During the same quarter last year, the business earned $0.23 earnings per share. Equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post $0.27 earnings per share for the current fiscal year.
Amphastar Pharmaceuticals announced that its Board of Directors has initiated a stock buyback plan on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.
A number of research firms have commented on AMPH. Jefferies Group LLC reaffirmed a “buy” rating and issued a $19.00 target price (down previously from $20.00) on shares of Amphastar Pharmaceuticals in a research report on Friday, August 11th. Piper Jaffray Companies set a $19.00 target price on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Needham & Company LLC lifted their target price on shares of Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, September 27th. Finally, ValuEngine downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average price target of $20.17.
In other news, EVP Diane G. Gerst sold 8,444 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $18.87, for a total value of $159,338.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $14.81, for a total transaction of $148,100.00. Following the completion of the sale, the director now owns 33,844 shares in the company, valued at approximately $501,229.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 126,380 shares of company stock worth $2,268,933. Company insiders own 11.10% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.